sNfL as a predictor of 10-year gray matter atrophy and clinical disability in MS

Synaptic loss in the retina as a predictor of progression in MSПодробнее

The association between neurodegeneration and PIRA in MSПодробнее

CMSC 2020 Day 1: Patricia Coyle, MD on Progressive MS: Dx, Clinical Course and Long-Term ManagementПодробнее

Measuring treatment responses in progressive MS with MRIПодробнее

Evaluation of sNfL in MS patients with NEDA-3Подробнее

Elevated sNfL associated with brain atrophy and new T2 lesionsПодробнее

The predictive value of NEDA-3 for long-term disability in MSПодробнее

Prof. Richard Reynolds (Imperial College London) on grey matter atrophy in Multiple SclerosisПодробнее

Current Concepts in Multiple Sclerosis Part 1Подробнее

webinar - Dr. Rovira & Dr. Sastre-Garriga on Atrophy in MS | May 2020Подробнее

The clinical presentation of MS in Latin American populationsПодробнее

Promising biomarkers in MS: serum NfL & GFAPПодробнее

Promising Effects of Vidofludimus Calcium by Age and Disability in Progressive MSПодробнее

Cognitive impairment associates with brain volume loss in multiple sclerosisПодробнее

sNfL and Radiologic Disease Activity in Patients With MSПодробнее

The influence of gadolinium-based contrast agents on atrophy measurements in MSПодробнее

Serum neurofilament levels are associated with health outcomes and resource use in MSПодробнее

A Worse MS Prognosis?Подробнее

Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer’s diseaseПодробнее